Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + trastuzumab + albumin-bound paclitaxel first-line study in HER2-positive recurrent/metastatic breast cancer
ChiCTR2000030618Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pyrotinib, trastuzumab and paclitaxel in breast cancer, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-free survival. Started Mar 2020; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2000030618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030618.